AU2013310924B2 - Method for producing antibody molecules having inter-species, intra-target cross-reactivity - Google Patents

Method for producing antibody molecules having inter-species, intra-target cross-reactivity Download PDF

Info

Publication number
AU2013310924B2
AU2013310924B2 AU2013310924A AU2013310924A AU2013310924B2 AU 2013310924 B2 AU2013310924 B2 AU 2013310924B2 AU 2013310924 A AU2013310924 A AU 2013310924A AU 2013310924 A AU2013310924 A AU 2013310924A AU 2013310924 B2 AU2013310924 B2 AU 2013310924B2
Authority
AU
Australia
Prior art keywords
species
target
antigen
immune library
reactivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013310924A
Other languages
English (en)
Other versions
AU2013310924A1 (en
AU2013310924A8 (en
Inventor
Christophe Frederic Jerome Blanchetot
Johannes Joseph Wilhelmus De Haard
Sebastian Paul VAN DER WONING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Publication of AU2013310924A1 publication Critical patent/AU2013310924A1/en
Publication of AU2013310924A8 publication Critical patent/AU2013310924A8/en
Priority to AU2017204188A priority Critical patent/AU2017204188A1/en
Application granted granted Critical
Publication of AU2013310924B2 publication Critical patent/AU2013310924B2/en
Assigned to ARGENX BVBA reassignment ARGENX BVBA Request for Assignment Assignors: ARGEN-X NV
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2013310924A 2012-08-31 2013-08-30 Method for producing antibody molecules having inter-species, intra-target cross-reactivity Active AU2013310924B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017204188A AU2017204188A1 (en) 2012-08-31 2017-06-21 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695664P 2012-08-31 2012-08-31
US61/695,664 2012-08-31
PCT/EP2013/067979 WO2014033252A1 (en) 2012-08-31 2013-08-30 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017204188A Division AU2017204188A1 (en) 2012-08-31 2017-06-21 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Publications (3)

Publication Number Publication Date
AU2013310924A1 AU2013310924A1 (en) 2015-01-29
AU2013310924A8 AU2013310924A8 (en) 2015-04-30
AU2013310924B2 true AU2013310924B2 (en) 2017-08-03

Family

ID=49080903

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013310924A Active AU2013310924B2 (en) 2012-08-31 2013-08-30 Method for producing antibody molecules having inter-species, intra-target cross-reactivity
AU2017204188A Abandoned AU2017204188A1 (en) 2012-08-31 2017-06-21 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017204188A Abandoned AU2017204188A1 (en) 2012-08-31 2017-06-21 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Country Status (10)

Country Link
US (1) US20150203840A1 (cg-RX-API-DMAC7.html)
EP (2) EP2890711B1 (cg-RX-API-DMAC7.html)
JP (1) JP6391574B2 (cg-RX-API-DMAC7.html)
CN (1) CN104583238A (cg-RX-API-DMAC7.html)
AU (2) AU2013310924B2 (cg-RX-API-DMAC7.html)
CA (1) CA2878712A1 (cg-RX-API-DMAC7.html)
DK (1) DK2890711T3 (cg-RX-API-DMAC7.html)
IL (1) IL236523B (cg-RX-API-DMAC7.html)
IN (1) IN2015DN00140A (cg-RX-API-DMAC7.html)
WO (1) WO2014033252A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012228194B2 (en) 2011-03-16 2017-06-01 Argenx Bvba Antibodies to CD70
JP2016529892A (ja) 2013-08-01 2016-09-29 ユニベルシテ カソリク デ ロウバイン 抗ｇａｒｐタンパク質及びその使用
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
CA3030099A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
EP3723803A4 (en) 2017-12-12 2021-09-15 Pionyr Immunotherapeutics, Inc. ANTI-TREM2 ANTIBODIES AND RELATED PROCEDURES
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
CN112004826B (zh) 2018-02-05 2024-06-14 自由大学基金会 反向激动性抗us28抗体
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
TW202200623A (zh) * 2020-05-29 2022-01-01 日商第一三共股份有限公司 對炎症性腸病之治療用抗體
EP4277706A1 (en) 2021-01-15 2023-11-22 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
WO2024096735A1 (en) 2022-10-31 2024-05-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
WO2024101989A1 (en) 2022-11-08 2024-05-16 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
EP4631501A1 (en) 2024-04-09 2025-10-15 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combinations of a calcium homeostasis disruptor with a death receptor 5 agonist for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085476A2 (en) * 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
EP2316852A1 (en) * 2002-11-08 2011-05-04 Ablynx N.V. Stabilized single domain antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU760562B2 (en) * 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
CN1735629B (zh) * 2002-11-08 2012-05-09 埃博灵克斯股份有限公司 针对肿瘤坏死因子-α的单结构域抗体及其用途
UA93179C2 (ru) * 2003-03-24 2011-01-25 Займоджинетикс, Инк. Антитело, kotopoe специфически связывается c il-22ra, и способы его применения
PL2163562T3 (pl) * 2005-06-21 2014-03-31 Xoma Us Llc Przeciwciała wiążące IL-1 beta i ich fragmenty
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
CN107337734A (zh) * 2009-12-04 2017-11-10 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
KR20180069083A (ko) * 2010-11-24 2018-06-22 렉시컨 파마슈티컬스 인코퍼레이티드 노텀 펙틴아세틸에스터라제에 대한 항체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316852A1 (en) * 2002-11-08 2011-05-04 Ablynx N.V. Stabilized single domain antibodies
WO2004085476A2 (en) * 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Also Published As

Publication number Publication date
EP2890711B1 (en) 2017-01-04
AU2017204188A1 (en) 2017-07-13
CA2878712A1 (en) 2014-03-06
JP2015530087A (ja) 2015-10-15
JP6391574B2 (ja) 2018-09-26
IL236523A0 (en) 2015-02-26
CN104583238A (zh) 2015-04-29
IL236523B (en) 2018-12-31
AU2013310924A1 (en) 2015-01-29
EP2890711A1 (en) 2015-07-08
AU2013310924A8 (en) 2015-04-30
WO2014033252A1 (en) 2014-03-06
IN2015DN00140A (cg-RX-API-DMAC7.html) 2015-06-12
US20150203840A1 (en) 2015-07-23
EP2977386A1 (en) 2016-01-27
DK2890711T3 (en) 2017-02-27

Similar Documents

Publication Publication Date Title
AU2013310924B2 (en) Method for producing antibody molecules having inter-species, intra-target cross-reactivity
US11629434B2 (en) Antibody screening methods
Liu et al. Isolation of anti-toxin single domain antibodies from a semi-synthetic spiny dogfish shark display library
US12442106B2 (en) Sequence-based high throughput method generating camelids antibodies to cover broad epitopes with high-resolution
JP5791496B2 (ja) 推定成熟ｃｄｒのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化
AU2019203048A1 (en) Express humanization of antibodies
JP7695881B2 (ja) 操作されたｃｄ２５ポリペプチドおよびその使用
JP2017538656A (ja) 可変ドメインｖｌおよびｖｈｈ誘導体に基づく高アフィニティおよび凝集耐性抗体
KR20200047606A (ko) Il-6r 항체와 이의 항원 결합 단편 및 의학적 용도
WO2022037527A1 (zh) 结合bcma的单可变结构域及抗原结合分子
US9090994B2 (en) Antibody humanization by framework assembly
CN116023495A (zh) 一种抗cd40纳米抗体及其制备方法与应用
Ren et al. The role of the light chain in the structure and binding activity of two cattle antibodies that neutralize bovine respiratory syncytial virus
WO2022037528A1 (zh) 结合bcma的单可变结构域及抗原结合分子
US20250092124A1 (en) Antibody molecule against growth and differentiation factor 15 and use thereof
CN121219319A (zh) 抗tigit抗体及其应用
HK40047350A (en) Antibody screening methods
HK40047350B (en) Antibody screening methods
KR20240150779A (ko) 고양이과 항체 라이브러리
CN120098123A (zh) 一种特异性结合Hb-CS蛋白的抗体、其抗原结合片段及其应用
CN117990807A (zh) 一种抗tslp单克隆抗体电荷异质性的检测方法
CN117836308A (zh) 用于选择特异性结合剂的手段和方法

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 29 , NO 3 , PAGE(S) 551 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ARGEN-X BV, APPLICATION NO. 2013310924, UNDER INID (71) CORRECT THE APPLICANT NAME TO ARGEN-X NV

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ARGENX BVBA

Free format text: FORMER OWNER(S): ARGEN-X NV